ALCON INC ALC

Alcon Inc files with the US Securities and Exchange Commission under CIK 0001167379, and the submissions JSON pulled for this report is dominated by foreign issuer 6-K filings rather than current results. The standout entries are clinical: one titled '6K RETAANE PHASE III TRIALS' and a companion, 'PRS POLL & RETAANE 24 MONTH RESULTS'. Both point to a company whose central work is treating eye disease, with Retaane aimed at the wet form of age-related macular degeneration.

This is, on the evidence supplied, an ophthalmic business. The same feed names brimonidine, the active ingredient behind a glaucoma press release ('6K PRESS RELEASE BRIMONIDINE'), and LadarVision, the laser vision correction system referenced in 'PRESS RELEASES ON RETAANE AND LADARVISION'. That matters because it tells the reader what the company actually sells: medicines and devices for sight, where regulatory approval and multi-year trial data, not quarterly slogans, decide whether a product reaches patients.

On dated filings, the rail surfaced 'FINANCIAL STATEMENTS Q1 2003', '6K THIRD QTR 2003 OPERATING RESULTS - ALCON, INC.', a matching 'Q3 2003 NEWS RELEASE' and 'ALCON Q3 2003 WEBCAST SLIDES', plus a later 'PRESS RELEASE - ALCON Q2 2004 PRE-ANNOUNCEMENT' and 'RECLASSIFICATION OF 2001-2002 SALES BY CATEGORY'. These are the period labels the feed carries. Crucially, the rail returned the titles of these documents and not the figures inside them, so this report cannot quote a revenue, profit, earnings-per-share or cash number; none has been parsed.

The source list contains no chart route, only the EDGAR submissions feed, so there are no levels, ranges or candles to discuss and none will be invented here. The mechanism worth understanding is what a submissions JSON is: an index of a company's filings with their forms and titles, useful for confirming that a document was filed and when, but silent on the contents of each filing unless those documents are fetched and read directly.

What changed, on this rail, were two corporate events the feed names plainly: '6K SALE OF MADRID PLANT', a manufacturing divestment, and 'PRESS RELEASE - CHANGE IN ALCON MANAGEMENT', a leadership move. What remains unproven is everything that gives those headers meaning: the trial endpoints behind Retaane, the terms of the Madrid sale, the names in the management change, and any current financial figure. The file would deepen the moment the underlying 6-K documents are parsed and the EDGAR pull is extended past its most recent dated entry, the Q2 2004 pre-announcement.